European perspective on multiple myeloma treatment strategies in 2014 - Wikidata - thesis-toulmin - TriplyDB

European perspective on multiple myeloma treatment strategies in 2014

European perspective on multiple myeloma treatment strategies in 2014

http://www.wikidata.org/entity/Q27005966

about

Treatment of relapsed and refractory multiple myeloma Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study.Therapeutic Efficacy and Cost Effectiveness of High Cut-Off Dialyzers Compared to Conventional Dialysis in Patients with Cast Nephropathy.Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System.Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.Design Issues in Randomized Clinical Trials of Maintenance Therapies.The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials.The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma.Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis.Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores.Current therapeutic strategies for multiple myeloma.Oral ixazomib maintenance therapy in multiple myeloma.The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling.The role of tandem stem cell transplantation for multiple myeloma patients.Long-term disease control in a refractory multiple myeloma patient treated with bortezomib mono-therapy: a case report and review of literature.A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients.Overexpression of salivary-type amylase reduces the sensitivity to bortezomib in multiple myeloma cells.Multiple myeloma: practice patterns across Europe.Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study.Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactions New insights into malignant B-cell disorders.Epha3 acts as proangiogenic factor in multiple myeloma.Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies.Autotransplants in older multiple myeloma patients: hype or hope in the era of novel agents?Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis.Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.Cost analysis of a randomized stem cell mobilization study in multiple myeloma.Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents.A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.

P2860

Q26749180-44FF3C69-3D2D-4497-AFA0-D8C5866D26DC Q26768699-0CFC8849-A669-4AE1-957F-708912AEBD28 Q28075927-4ABBE1B9-3431-43F4-ACCB-EDF5E3F04B17 Q35832484-59FC10C3-FA02-4A82-B716-F0C4E7EB5E94 Q36088601-A4A9F106-0139-49ED-87F8-7609EB18A092 Q36193181-3DC25709-A93A-499C-B8B1-F4A714BFC318 Q36592788-3F9BB0AF-8728-4E67-B531-9CF0D9109AAE Q36848078-5615CCC3-DD7B-4759-B762-BF38318C8A7C Q37384918-6B76A7C1-CAA8-47C5-A583-07071930037A Q37414394-0BECD58F-6985-43E6-A196-4295206F7BEB Q37708798-2C6EEF61-F8B8-490A-9B86-ECA5D5A67C0B Q38389362-CE695C37-0CD8-43D4-86FB-482FE77A789A Q38412189-6135C6A8-B7ED-4748-9F9D-5E1EFCB679C3 Q38640514-7BC06042-00A2-4965-8A96-1C1583478913 Q38656507-D24F6B1E-2976-40E2-8683-290212D2A432 Q38677358-17828562-9B00-481C-AB3C-61ABDB4CA00A Q38697604-57B4E94B-2603-4EBB-A9E7-C8A9AE71B0EF Q38762572-49A3227B-D7BE-401D-8F50-28DDA31FBB8A Q38837700-F2291513-12E2-459C-A465-7DD705B79D08 Q38862553-7F860354-FC61-4D55-BE54-9B557516DFB5 Q39070193-D475AFFE-F4AE-45F9-B6B4-9E73DE1A2FFC Q39071875-224CE2A5-383A-4283-8EA2-337104D7C484 Q40047253-C33141BE-1D67-4ED7-8472-A4BB7918E132 Q41620033-C9EE07E2-1A2F-40EC-B5A0-E9AE11DB1783 Q42147033-CE2248FC-A7BC-4E58-B977-35F0509C83F6 Q42174452-A1D8C534-F4B6-4BFC-8D01-181A0892C935 Q42331654-3423F370-A784-4E9A-86F4-159B76E87F9B Q42362041-20969502-4D46-4A8B-8763-EC05C4FE83BB Q46432419-3FBD241A-1455-40CA-A722-3912633144BB Q47248893-89F16549-8130-4449-9E4B-10C5D1E8CFEF Q47348957-4DB79AF2-B631-426F-A33E-D8945889A164 Q48130246-7863C7B1-4C76-4633-A55B-91E9C058DD39 Q48958626-C9FD87BA-D2BA-42F5-A509-A423E86CF2FF Q50860596-044B6337-B581-4909-9B55-7E7299BAB0D2

P2860

European perspective on multiple myeloma treatment strategies in 2014

http://www.wikidata.org/entity/Q27005966

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

European perspective on multiple myeloma treatment strategies in 2014

@ast

European perspective on multiple myeloma treatment strategies in 2014

@en

European perspective on multiple myeloma treatment strategies in 2014

@nl

type

label

European perspective on multiple myeloma treatment strategies in 2014

@ast

European perspective on multiple myeloma treatment strategies in 2014

@en

European perspective on multiple myeloma treatment strategies in 2014

@nl

prefLabel

European perspective on multiple myeloma treatment strategies in 2014

@ast

European perspective on multiple myeloma treatment strategies in 2014

@en

European perspective on multiple myeloma treatment strategies in 2014

@nl

P1433

Q27005966-C7114860-711A-437B-8E76-E6972EAE2AE2

P1476

Q27005966-C7588276-6D23-42CC-835D-B12DBBEEB3A4

P2093

Q27005966-067AAD54-EAE1-4E85-BF6F-138E82B066A5

Q27005966-120AEDD5-6A2C-4C64-A8B5-C6D9E34305A5

Q27005966-225F9D0F-4FB9-423E-BC83-9ED761E41395

Q27005966-599C8FF5-591E-4F27-9323-5B22FEEDB65F

Q27005966-6C190144-E374-4AD2-86AD-F61C54154ADD

Q27005966-B357E6B5-2880-41A8-9849-64013C4B7A4D

Q27005966-D3639385-E060-45A7-8296-FFA78120B20D

Q27005966-EE6C9063-2A32-4A3B-98EC-A9F6C2CDEC77

P2860

Q27005966-00A86184-53D0-48B8-9A3C-5569280E6E23

Q27005966-0432E96D-FEA2-4199-B8D9-FF1B419E58C0

Q27005966-06D17C05-5D30-404D-A602-DDD52DD1DA52

Q27005966-0964A5E7-C072-48EB-939D-568FC5C128CA

Q27005966-0C2C6CD8-E2F7-4ED1-98E3-C4BD5704B6E9

Q27005966-0C49899D-0EFA-4EC4-A245-F654667C1F61

Q27005966-0EF8511D-9DD8-420E-BA55-F21A1E1D4487

Q27005966-127356D2-5F1D-4BF8-AF0F-8AE22682D087

Q27005966-14DF00FB-7B4E-464E-8AC5-A818B5F0992B

Q27005966-19B3AFDE-740D-4B0A-B1B8-C03C54A13F51

P304

Q27005966-90878B38-DAD2-4320-8B4B-634DE83BA51E

P31

Q27005966-9B6181D3-1084-41DA-90E9-A17CAAE65199

P3181

Q27005966-A317C747-7725-4681-863B-852F90E78941

P356

Q27005966-0600B4BD-2CB8-4004-A625-4A08F2985DAB

P407

Q27005966-1A20D7A8-C628-4D92-BB59-247D2C3F0240

P433

Q27005966-530F046F-58DA-4484-8483-CC28E8594748

P478

Q27005966-BEC4D01B-956A-48CA-A270-A94BACEFACDF

P50

Q27005966-1503878D-B6C2-4EE3-96BE-4CB8F99C5369

Q27005966-1C716192-D7B2-4726-9AF3-5ACF7363CAD6

Q27005966-30E1643E-C257-4D5F-8986-E508DA6CE8FD

Q27005966-43E09166-89F3-44A9-9A05-01265A7F94A6

Q27005966-449CB786-47AE-4D67-9939-22A203E8BCCE

Q27005966-44C8E89A-74EA-47B4-B1BD-009BCB3CF517

Q27005966-4C6C5250-4652-4665-853F-E9ADFC70305F

Q27005966-51B2943C-563D-43BB-B53D-1D8DDA482D86

Q27005966-55048768-FF56-4DC6-AB8E-266BFE2580D9

Q27005966-A13DB068-FAA1-4C0F-BEDF-CD462D62841E

P577

Q27005966-CA072A7C-DFCA-4F24-B522-1C111DF3D1C3

P5875

Q27005966-CB343078-54D3-4E8B-B872-8DD03E563E14

P698

Q27005966-E12A59BC-BAD9-4BE6-8725-24D822B08B8B

P932

Q27005966-99C1A273-DB79-4032-AE30-DF14FD813A03

P3181

P356

THEONCOLOGIST.2014-0042

P1433

P1476

European perspective on multiple myeloma treatment strategies in 2014

@en

P2093

Faith Davies

http://www.w3.org/2001/XMLSchema#string

Hermann Einsele

http://www.w3.org/2001/XMLSchema#string

Joan Bladé

http://www.w3.org/2001/XMLSchema#string

Mario Boccadoro

http://www.w3.org/2001/XMLSchema#string

Michel Delforge

http://www.w3.org/2001/XMLSchema#string

Pia Sondergeld

http://www.w3.org/2001/XMLSchema#string

Pieter Sonneveld

http://www.w3.org/2001/XMLSchema#string

Torben Plesner

http://www.w3.org/2001/XMLSchema#string

P2860

First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies

Initial genome sequencing and analysis of multiple myeloma

Smoldering multiple myeloma requiring treatment: time for a new definition?

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials

Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.

Salvage second hematopoietic cell transplantation in myeloma

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.

Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma.

Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.

P304

829-844

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4261782

http://www.w3.org/2001/XMLSchema#string

P356

10.1634/THEONCOLOGIST.2014-0042

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Hartmut Goldschmidt

Meletios A. Dimopoulos

Javier de la Rubia

Jesus San Miguel

Gareth J Morgan

Antonio Palumbo

P577

2014-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264245101

http://www.w3.org/2001/XMLSchema#string

P698

25063227

http://www.w3.org/2001/XMLSchema#string

P932

4122482

http://www.w3.org/2001/XMLSchema#string